Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2446 to 2460 of 8905 results

  1. Arthrosamid for symptomatic treatment of knee osteoarthritis

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  2. Levodopa, carbidopa monohydrate and entacapone intestinal gel for treating the symptoms of advanced Parkinson's disease [ID4005]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

    Topic prioritisation

    Highly specialised technologies guidance
    Topic prioritisation

  5. Nitisinone for treating alkaptonuria [ID2691]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Remimazolam for general anaesthesia [ID3796]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Prolonged-release diazoxide choline for treating Prader-Willi syndrome [ID1389]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Canakinumab for untreated Schnitzler syndrome [ID4063]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma (DLBCL) [TSID12334]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Gilteritinib + daunorubicin + cytarabine for Acute myeloid leukaemia (AML) [TSID12331]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Subcutaneous amivantamab for treating advanced non-small-cell lung cancer with EGFR mutations [TSID12011]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Ivacaftor–tezacaftor–elaxcaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in people 1 to under 2 years [TSID12295]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Xeomin (botulinum neurotoxin type A) for treating lower or upper limb spasticity in people 2 to 17 years [TSID12297]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation